Posted on

dea makes cbd oil schedule 1

When a product is in violation of the FD&C Act, FDA considers many factors in deciding whether or not to initiate an enforcement action. Those factors include, among other things, agency resources and the threat to the public health. FDA also may consult with its federal and state partners in making decisions about whether to initiate a federal enforcement action.

The agency has and will continue to monitor the marketplace and take action as needed to protect the public health against companies illegally selling cannabis and cannabis-derived products that can put consumers at risk and that are being marketed for therapeutic uses for which they are not approved. At the same time, FDA recognizes the potential therapeutic opportunities that cannabis or cannabis-derived compounds could offer and acknowledges the significant interest in these possibilities. FDA continues to believe that the drug approval process represents the best way to help ensure that safe and effective new medicines, including any drugs derived from cannabis, are available to patients in need of appropriate medical therapy. The Center for Drug Evaluation and Research (CDER) is committed to supporting the development of new drugs, including cannabis and cannabis-derived drugs, through the investigational new drug (IND) and drug approval process (see Question #16).

[2] Gunn, et al. Prenatal Exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016; 6:e009986.

Questions and Answers

FDA continues to be concerned at the proliferation of products asserting to contain CBD that are marketed for therapeutic or medical uses although they have not been approved by FDA. Often such products are sold online and are therefore available throughout the country. Selling unapproved products with unsubstantiated therapeutic claims is not only a violation of the law, but also can put patients at risk, as these products have not been proven to be safe or effective. This deceptive marketing of unproven treatments also raises significant public health concerns, because patients and other consumers may be influenced not to use approved therapies to treat serious and even fatal diseases.

Hemp seeds are the seeds of the Cannabis sativa plant. The seeds of the plant do not naturally contain THC or CBD. The hemp seed-derived ingredients that are the subject of these GRAS notices contain only trace amounts of THC and CBD, which the seeds may pick up during harvesting and processing when they are in contact with other parts of the plant. Consumption of these hemp seed-derived ingredients is not capable of making consumers “high.”

Consumer Information

15. Can I import or export cannabis-containing or cannabis-derived products?

19. Can patients gain access to cannabis or cannabis-derived products for medical use through Right to Try?

Dea makes cbd oil schedule 1

With different forms of cannabis being legalized on both a state and federal level, CBD’s class schedule continues to be complex and confusing for some. All the while,, the CBD market continues to skyrocket as more and more companies produce, distribute, and sell CBD products, and as consumers across the world buy CBD products in increasing numbers.

The DEA and US Food and Drug Administration (FDA) are in charge of determining which substances should be added, removed, or re-classified. Schedule I substances are presumed to be the most dangerous with a high potential for abuse and no perceived health benefit and tend to be the most heavily criminalized, while Schedule V substances as defined as drugs with the lowest potential for abuse. Examples of Schedule I drugs include heroin, methamphetamines, LSD, and cannabis.

According to the FDA, CBD derived from hemp plants is still not approved for use in medicinal products or in food and drink products. In September 2018, prior to the passage of the 2018 Hemp Farming Bill, the DEA released a statement announcing that CBD products that had been approved by the U.S. Food and Drug Administration (FDA) and contain less with THC levels below .1% would be classified as a Schedule V substance.

State laws are the other consideration when it comes to the legal status of CBD. Currently, hemp-derived CBD is legal in most states. As a result, it is increasingly easy to find CBD products in many cities and states despite the technicalities of federal law. Additionally, in certain states with medical marijuana legalization, CBD products containing THC are also permitted for qualifying patients. CBD products with more than .3% THC are also legalized in states with adult-use programs in place.

Image lightbox

This has put CBD into an interesting legal position, leading to confusion of whether CBD oil is a federally restricted Schedule I substance or is now federally legal. At the federal level, legality all depends on what type of plant the CBD comes from, as well as how much THC is present in both the original plant and the final product.

However, the list of FDA approved drugs that contain cannabis-derived compounds remains limited to a single CBD-based product: an epilepsy medicine called Epidiolex, made by GW Pharmaceuticals. Any other medication is technically not approved under federal law and would, therefore, be considered illegal at the federal level, which is why CBD producers are not permitted to make health claims about their products.

Under federal law, CBD that is derived from cannabis plants with more than .3% THC is considered illegal, as the intoxicating cannabinoid remains a Schedule I substance. If the cannabis plant has more than .3% THC, then all substances derived from it — including any CBD extracted from the plant — are considered by the DEA to be a federally restricted Schedule I substance.

Image lightbox

To date, researchers have identified several health benefits and possible therapeutic uses of CBD, including anti-inflammatory, anti-anxiety, and numerous neuroprotective qualities.

The 2014 Hemp Farming Bill created a framework for the legal cultivation of industrial hemp without requiring a permit from the DEA. Four years later, the passage of the Hemp Farming Act of 2018 which was signed into law by President Donald Trump in November 2018, introduced a new legal channel through which certain types of CBD can be considered legal. The measure removed industrial hemp plants from its earlier status as a controlled substance, shifting oversight from the DEA to the FDA.

Dea makes cbd oil schedule 1

“This action is beyond the DEA’s authority,” Robert Hoban, a Colorado cannabis attorney and adjunct professor of law at the University of Denver, told the International Business Times. “The DEA can only carry out the law, they cannot create it. Here, they’re purporting to create an entirely new category called ‘marijuana extracts,’ and by doing so wrest control over all cannabinoids. They want to call all cannabinoids illegal. But they don’t have the authority to do that.”

Tell that to the thousands of epilepsy sufferers, who are mercifully enjoying relief from intractable epilepsy and polymorphic seizures.

“It’s an internal accounting mechanism for us,” DEA spokesperson Russell Baer told VICE News. “The purpose is to drill down and get more accurate information about research that’s being conducted with CBD in particular.”

In addition to the fact that this move is likely illegal, it is clearly backward and could obstruct medical research efforts that have already produced effective CBD-derived medications. One such medication is Epidiolex, developed by GW Pharmaceuticals for the treatment of Dravet’s Syndrome, which recently came one step closer to FDA approval.

Under their new drug code, entitled “Establishment of a New Drug Code for Marihuana Extract,” the DEA announced it was “creating a separate code number for marihuana extract with the following definition: ‘Meaning an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant.’ Extracts of marihuana will continue to be treated as Schedule I controlled substances.”

The DEA is essentially giving itself license to better track which scientists are studying marijuana and which ones are researching CBD and other extracts. At the moment, when researchers apply to the DEA for permission to study weed, there’s no way for them to specify whether they intend to only work on extracts.

On Wednesday, the DEA took yet another swipe at marijuana by amending its already bizarre classification of pot as a Schedule I drug. Now, all extracts, including cannabidiol (CBD), will be listed right up there with heroin as a “drug with no medical use.”

Photo by Getty Images

The idea of classifying weed and now CBD, as well as cannabis extracts (psychoactive or not), as a Schedule 1 drug, along with heroin is nothing less than an outrage.